Our Ph.D. student Derick Jones represented the group at this year’s NOBCChE conference. His photo appeared in C&EN! (C&EN Volume 95 Issue…
A press release from our partner company reports that our newest generation of cancer-fighting drugs is ten billion times more potent than…
Lex’s excellence in the research lab was recognized with the awarding of the Lilian Nile Undergraduate Research Assistantship at the 2017 Homecoming….
In preclinical results, our lead cancer drug, TLD-1433, has been shown to destroy the human brain cancer glioblastoma multiforme (GBM) when activated…
Our article Novel Osmium-based Coordination Complexes as Photosensitizers for Panchromatic Photodynamic Therapy is the feature article in the journal Photochemistry and Photobiology….
A recent publication in Inorganic Chemistry uses computational tools to validate the TypeI/TypeII dual mode activity in our cancer drugs. See our…
A second patent (US #9,676,806) has been granted for our high-potency photodynamic cancer drugs.
Our lead anti-cancer drug has been granted US patent number 9,345,769.
Our 2013 article [14] made the list of most cited publications in Photodiagnosis and Photodynamic Therapy for the past 5 years!
The McFarland group is now up and running at the University of North Carolina at Greensboro. Your days are numbered, cancer!!